StockData
InflaRx N.V. logo

InflaRx N.V. (IFRX) company profile

IFRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 20, 2026Score 5/30
$1.15−0.03 (-2.54%)

Close on Nov 17, 2026Market cap $83.14MP/E –Yield –

About InflaRx

Pharmaceutical Preparations, SIC 2834

InflaRx N.V. is a biopharmaceutical company that discovers and develops treatments for complement-mediated inflammatory and immunological diseases. The company utilizes proprietary anti-C5a and anti-C5aR technologies to target debilitating conditions. Its primary product is vilobelimab, marketed as GOHIBIC, which holds emergency use authorization in the United States and marketing authorization in Europe for treating severe COVID-19. InflaRx also develops vilobelimab for additional inflammatory indications, alongside pipeline candidates including izicopan and IFX002. These therapies target patients suffering from severe immune disorders and the healthcare systems that treat them.

The company is incorporated under Dutch law and maintains its principal executive offices and headquarters in Jena, Germany. InflaRx operates with a compact workforce, and substantially all of its assets are situated outside the United States. Furthermore, the majority of its directors and executive officers live outside the United States. Its clinical and commercial supply relationships with contract manufacturers span Europe and the United States.

Summary of the business section of InflaRx's latest annual report, written by StockData.

Company profile

Company

Legal name
InflaRx N.V.
Headquarters
Jena, 2M
Address
Winzerlaer Str. 2 07745
Phone
49 3641 508180
Website
inflarx.de
Industry
Pharmaceutical Preparations
Incorporated in
P7
Fiscal year ends
December 31
Auditor
KPMG AG Wirtschaftsprufungsgesellschaft, Munich, Germany

Stock & identifiers

Ticker
IFRX
Exchange
Nasdaq
IPO date
Nov 8, 2017
Shares outstanding
72M, Dec 31, 2025
Filer category
Non-accelerated filer
SEC CIK
1708688
CUSIP
N44821101
FIGI
BBG00HZ6PLC3
Share class FIGI
BBG00HZ6PLD2
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Renfeng GuoChief Scientific Officer, Director1,762,144
Niels RiedemannChief Executive Officer, Director1,068,908
Thomas TaapkenChief Financial Officer3,500
Derval OCarrollSee Remarks–
Mark KublerDirector960,015
Nicolas FulpiusDirector490,052
Hege HellstromDirector–
Anthony S. GibneyDirector10,000
Richard BrudnickDirector50,000

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 8, 2017
Offer price
$15.00
Securities offered
6,667,000
Gross proceeds
$100.01M
Exchange
Nasdaq
First trading day
Nov 7, 2017
First-day close
$15.000.0%
Lock-up ends (est.)
May 6, 2018

“The initial public offering price is $15.00 per common share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

DateEventDetails
Nov 8, 2017IPOInitial public offering priced (424B4 prospectus)
Nov 8, 2017Name changeName changed from Fireman B.V. to InflaRx N.V.
Nov 7, 2017ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?